SHIP1 is a hematopoietic specific inhibitory molecule whose alterations could contribute to the development of certain types of malignant hematopoietic disorders, including chronic myelogenous leukemia (CML), acute myelogenous leukemia (AML), and T-ALL [76]. Here, INPP5D is linked to chronic myelogenous leukemia, BCR-ABL1 positive.